Suppr超能文献

中国陕西省的药品价格、可及性与可负担性:对未来的启示

Medicine prices, availability, and affordability in the Shaanxi Province in China: implications for the future.

作者信息

Jiang Minghuan, Zhou Zhongliang, Wu Lina, Shen Qian, Lv Bing, Wang Xiao, Yang Shimin, Fang Yu

机构信息

Department of Pharmacy Administration, School of Pharmacy, Health Science Center, Xi'an Jiaotong University, 76 Yanta West Road, Xi'an, 710061, People's Republic of China.

出版信息

Int J Clin Pharm. 2015 Feb;37(1):12-7. doi: 10.1007/s11096-014-0037-4. Epub 2014 Nov 26.

Abstract

BACKGROUND

In 2009, China implemented the National Essential Medicines System (NEMS) to improve access to high-quality low-cost essential medicines.

OBJECTIVE

To measure the prices, availability and affordability of medicines in China following the implementation of the NEMS.

SETTING

120 public hospitals and 120 private pharmacies in ten cities in Shaanxi Province, Western China.

METHOD

The standardized methodology developed by the World Health Organization and Health Action International was used to collect data on prices and availability of 49 medicines.

MAIN OUTCOME MEASURES

Median price ratio; availability as a percentage; cost of course of treatment in days' wages of the lowest-paid government workers.

RESULTS

In the public hospitals, originator brands (OBs) were procured at 8.89 times the international reference price, more than seven times higher than the lowest-priced generics (LPGs). Patients paid 11.83 and 1.69 times the international reference prices for OBs and generics respectively. A similar result was observed in the private pharmacies. The mean availabilities of OBs and LPGs were 7.1 and 20.0 % in the public hospitals, and 12.6 and 29.2 % in the private pharmacies. Treatment with OBs is therefore largely unaffordable, but the affordability of the LPGs is generally good.

CONCLUSION

High prices and low availability of survey medicines were observed. The affordability of generics, but not OBs, is reasonable. Effective measures should be taken to reduce medicine prices and improve availability and affordability in Shaanxi Province.

摘要

背景

2009年,中国实施了国家基本药物制度(NEMS),以提高人们获得高质量低成本基本药物的机会。

目的

评估国家基本药物制度实施后中国药品的价格、可及性和可负担性。

地点

中国西部陕西省十个城市的120家公立医院和120家私立药店。

方法

采用世界卫生组织和国际卫生行动组织制定的标准化方法,收集49种药品的价格和可及性数据。

主要观察指标

中位数价格比;可及性百分比;以政府最低工资标准工作人员日工资计算的疗程费用。

结果

在公立医院,原研品牌药(OBs)的采购价格是国际参考价格的8.89倍,比最低价仿制药(LPGs)高出7倍多。患者购买原研品牌药和仿制药分别支付国际参考价格的11.83倍和1.69倍。在私立药店也观察到类似结果。在公立医院,原研品牌药和最低价仿制药的平均可及率分别为7.1%和20.0%,在私立药店分别为12.6%和29.2%。因此,使用原研品牌药的费用大多难以承受,但最低价仿制药的可负担性总体良好。

结论

调查药品存在价格高和可及性低的情况。仿制药的可负担性合理,但原研品牌药并非如此。应采取有效措施降低陕西省药品价格,提高药品可及性和可负担性。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验